Business
Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company
About this update from Aethlon Medical, Inc.
[{"type":"text","content":"Conference Call to be Held Today at 4:30 p.m. ET\nSAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2023 and provided an update on recent developments. \n\nCompany Updates\nAethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids. These qualities of the Hemopurifier have potential applications in oncology, where cancer associated exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. Aethlon is also investigating the use of the Hemopurifier in the organ transplant setting, initially focusing on the potential removal of viruses and exosomes with harmful cargo from recovered kidneys.\nIn October 2023, Aethlon received clearance from the Drug Controller General of India (DCGI), the country's central drug authority, to conduct a phase 1 safety, feasibility and dose-finding trial of the Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®. The trial is expected to begin following completion of an in vitro binding study of relevant targets, and subsequent approval by the respective Ethics Boards of interested sites in India.\n\"In addition to an interested initial site in India, we have two interested sites in Australia that are also awaiting the data from our in vitro binding study,\" stated James Frakes, Interim Chief Executive Officer and Chief Financial Officer. \"Our in vitro binding study of relevant oncology targets is complex and stands on the cutting edge of extracellular vesicle science. Our goal is to quantify the potential impact of our Hemopurifier on plasma from cancer patients that have been treated with anti-PD-1 monotherapy treatment in order to provide pre-clinical evidence to support our trial design.\n\"While our research and development team has started to quantify our internal data, the results, to date, are inconclusive. Therefore, while our internal team continues ...